HR 909

Andrea Sloan CURE Act

Congress: 114 (2015–2017, Ended)
Chamber: House
Policy Area: Health
Introduced: Feb 12, 2015
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Feb 13, 2015)
Official Text: https://www.congress.gov/bill/114th-congress/house-bill/909

Sponsor

Name: Rep. McCaul, Michael T. [R-TX-10]
Party: Republican • **State:** TX • **Chamber:** House

Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Burgess, Michael C. [R-TX-26]	R · TX		Feb 12, 2015
Rep. Butterfield, G. K. [D-NC-1]	D · NC		Feb 12, 2015
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		Feb 12, 2015
Rep. Lance, Leonard [R-NJ-7]	R · NJ		Feb 12, 2015
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Feb 12, 2015
Rep. Fortenberry, Jeff [R-NE-1]	R · NE		Mar 16, 2015
Rep. Hanna, Richard L. [R-NY-22]	R · NY		Apr 13, 2015
Rep. Peters, Scott H. [D-CA-52]	D · CA		May 5, 2015
Rep. Walz, Timothy J. [D-MN-1]	D · MN		May 15, 2015
Rep. Cramer, Kevin [R-ND-At Large]	R · ND		Feb 1, 2016

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 13, 2015

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Feb 12, 2015)

Andrea Sloan Compassionate Use Reform and Enhancement Act or the Andrea Sloan CURE Act

Amends the Federal Food, Drug, and Cosmetic Act to require the sponsor of an “investigational drug” (which is a drug that is designated as a breakthrough therapy, fast track product, infectious disease product, or drug for a rare disease or condition) to submit to the Food and Drug Administration (FDA) and make available to the public the sponsor's policy on requests for expanded access to the unapproved drug, including the minimum criteria for considering or approving requests and the time needed to make a decision.

Requires an investigational drug sponsor to explain a denied request for expanded access to the person who made the request.

Directs the Department of Health and Human Services to establish an Expanded Access Task Force. Requires the Task Force and the Government Accountability Office (GAO) to evaluate patient access to investigational drugs and make recommendations for improving access.
Directs the FDA to finalize the draft guidance entitled “Expanded Access to Investigational Drugs for Treatment Use--Qs & As,” taking into account reports from the Task Force and GAO.

Actions Timeline

- **Feb 13, 2015:** Referred to the Subcommittee on Health.
- **Feb 12, 2015:** Introduced in House
- **Feb 12, 2015:** Referred to the House Committee on Energy and Commerce.